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Osteopontin (OPN) is a multifunctional protein, which has recently been shown to be linked to tumorigenesis, progression and
metastasis in different malignancies. Since non-small-cell lung cancer (NSCLC)’s prognosis remains bad, with few predictors of
outcome, the purpose of this study was to evaluate if OPN might be involved in NSCLC’s biology and therefore represent a
prognostic marker and a target for new therapeutic trials. Immunohistochemistry was used to detect OPN expression, evaluated as
percentage of neoplastic cells with cytoplasmic immunoreactivity, in a wide cohort of patients with stage I NSCLC (136 cases). The
median value of this series (20% of positive cells) was used as the cutoff value to distinguish tumours with low (o20%) from tumours
with high (X20%) OPN expression. A statistically significant correlation between high levels of OPN and shorter overall (P¼0.034)
and disease-free (P¼0.011) survival in our patients was shown. Our results support the hypothesis that high OPN expression is a
significantly unfavourable prognostic factor for the survival of patients with stage I NSCLC. This conclusion has notable importance in
terms of the biological characterization of early-stage tumours and therapeutic opportunities.
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Non-small-cell lung cancer (NSCLC) accounts for approximately
75% of all cases of lung cancer, which is one of the most common
tumours affecting humans in the world, and is the leading cause of
cancer-related deaths for both men and women in the US. Among
lung cancers, NSCLC is a subgroup of particular interest because of
its heterogeneity in terms of both histopathological classification
and clinical behaviour: in fact, up till now, the factors responsible
for the different outcomes among patients with the same stage of
disease are little known. Despite improvements in detection and in
surgical and medical treatments during the past two decades, the
clinical behaviour of NSCLC remains bad, with an unsatisfactory
survival of even stage I patients, who develop local recurrences and
distant metastases, or eventually die, in about 30–40% of the cases,
within 5 years after complete surgical resection, which is currently
the only potentially curative treatment for NSCLC. This observa-
tion underlines how important it is to identify novel pathological
parameters in addition to disease stage and, most of all, new
biological markers, in order to add further prognostic information,
select high-risk patients for aggressive adjuvant treatments and set
new anticancer therapies.
Osteopontin (OPN) is one of the factors that seems to be linked
to cancer development, progression and metastasis in different
malignancies. Osteopontin is a multifunctional protein, with a
protein backbone of about 32.5kDa and multiple sites (up to 28) of
phosphorylation (Sorensen et al, 1995) and cleavage. Indeed, OPN
takes part in a broad range of physiological events (Sodek et al,
2000), such as bone (Reinholt et al, 1990; Giachelli and Steitz,
2000) and vascular (Shijubo et al, 2000) remodelling and tissue
repair, as well as in pathological processes, like cell-mediated
immunity, dystrophic calcification, coronary stenosis, wound
healing and cancer metastasis (Denhardt et al, 2001).
Moreover, the observation that OPN protein or gene expression
levels are increased in many human tumours, including breast
(Tuck et al, 1997; Tuck and Chambers, 2001), lung (Chambers et al,
1996), prostate (Thalmann et al, 1999), colon (Agrawal et al, 2002),
ovarian (Kim et al, 2002) and gastric (Ue et al, 1998) cancer,
confirmed the hypothesis that it plays an important role in
tumorigenesis, tumour progression and metastasis (Oates et al,
1997; Furger et al, 2001). A notable consequence of the involvement
of OPN in dissemination of various solid tumours is that it could be
a specific target for anticancer therapy (Weber, 2001).
However, the impact of OPN on NSCLC outcome remains
unclear, with discordant data in spite of the numerous studies on
OPN expression conducted up till now using immunohistochem-
istry (IHC) and Northern blotting (Chambers et al, 1996; Shijubo
et al, 1999; Zhang et al, 2001). In the present work, we decided to
investigate OPN expression in a large series (136 cases) of stage I
NSCLC, in order to clarify the role that OPN plays in these tumours’
biology, and to define its usefulness as a prognostic marker in
identifying subsets of patients with a high risk of recurrence and
who would be suitable for adjuvant and new therapies.
Received 2 February 2005; revised 6 June 2005; accepted 20 June 2005;
published online 9 August 2005
*Correspondence: Professor G Fontanini; E-mail: g.fontanini@med.unipi.it
British Journal of Cancer (2005) 93, 453–457
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sMATERIALS AND METHODS
Patients and clinical data
A total of 136 patients with NSCLC, who consecutively underwent
radical surgical resection at the Department of Cardio-Thoracic
Surgery of the University of Pisa from December 1991 through
December 1994, were prospectively studied. No detectable
metastases in distal organs were present at the time of surgery.
No patient had received chemotherapy or radiotherapy before
surgery. The cohort of patients included 126 (92.6%) male and 10
(7.4%) female subjects, with a combined median age of 66 years
(mean age 64.6 years; range, 45–80 years). Follow-up lasted
through 30 June 2003, with a median follow-up period of 49
months for living patients (range, 2–137 months). Disease-free
survival and overall survival rates were calculated as the period
from surgery until the date of disease relapse or of death,
respectively.
Specimens
Neoplastic specimens were removed from the periphery of the
tumour masses, since the central region of a tumour is more often
subject to regressive alterations, and were formalin-fixed and
paraffin-embedded for histological and immunohistochemical
analysis. The pathologic features of the samples were classified
according to World Health Organization histologic criteria (World
Health Organization, 1982), and tumour staging was performed
according to the International Union Against Cancer (UICC) and
tumour-node-metastasis (TNM) classification (Mountain, 1997).
Immunohistochemistry
Osteopontin expression was detected by IHC using an anti-OPN
polyclonal antibody (R&D Systems Inc, Minneapolis, MN, USA;
dilution at 1:40). The antibody was applied to 5mm sections taken
from the most representative formalin-fixed, paraffin-embedded
tumour tissue specimen obtained from each of the 136 patients
with NSCLC, using the avidin–biotin–peroxidase complex meth-
od (Vectastatin Elite ABC kit; Vector Laboratories, Inc., Burlin-
game, CA, USA), following the manufacturer’s instructions. The
immunostaining was performed manually at room temperature.
The sections, mounted on glass slides, were deparaffinised through
serial baths in xylene, and then rehydrated in a graded series of
alcohol and water. To remove any endogenous peroxidase activity
and nonspecific background staining, the sections were soaked in
absolute methanol containing 0.3% hydrogen peroxide for 30min
at room temperature. After being washed with TBS (Tris-Buffer
Saline) for 5min, the slides were blocked with nonimmune rabbit
serum for 30min to inhibit nonspecific binding, followed by
incubation with the anti-OPN primary antibody for 60min at room
temperature. After rinsing with TBS for 5min, the sections were
subsequently incubated with biotin-conjugated goat anti-mouse
IgG antibody for 30min. Then, after being washed again with TBS
for 5min, the slides were incubated with avidin–biotin–perox-
idase complex for 30min and washed again with TBS. Finally, the
sections were incubated with 0.05% 3,30-diaminobenzidine tetra-
hydrochloride (Sigma, St Louis, MO, USA) and then rinsed in
distilled water. All slides were lightly counterstained with Mayer’s
haematoxylin for 30s, rinsed in running water, dehydrated and
mounted with Canadian balsam. No antigen retrieval was
performed. A section of thyroid papillary carcinoma, classic
variant, previously proven to be OPN positive by Western blot, was
used as positive control.
The immunohistochemical expression of OPN was evaluated as
the percentage of tumour cells with cytoplasmic immunoreactivity,
counting at least 1000 cancer cells (100 cells in 10 HPF) for each
section (Figure 1). The median value of this series (20% of positive
cells) was used as the cutoff value to distinguish tumours with low
(o20%) from tumours with high (X20%) OPN expression.
Figure 1 Osteopontin expression detected by immunohistochemical staining in two adenocarcinomas (A  100; B  200) and in two squamous-cell
carcinomas (C, D  200) of the lung.
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four categories: one negative (0), one with a weak staining (þ),
one with an intermediate staining (þþ) and one with a strong
staining (þþþ).
Statistical analysis
Statistical analysis was carried out using R 1.8.1 (R Development
Core Team, 2003). Univariate analysis was performed by modelling
Kaplan–Meier survival curves. Log rank test was used to evaluate
the statistical significance of differences in survival distributions.
Multivariate analysis was carried out using Cox proportional
hazard model. The proportional hazard assumption was tested as
proposed by Grambsch and Therneau (1994). Mann–Whitney and
Kruskal–Wallis tests were used to evaluate the associations
between the continuous-test variable-gene expression and patients’
clinicopathological parameters [Mann–Whitney test for dichot-
omous variables (sex; age: o66 years vs X66 years; squamous-cell
carcinomas vs nonsquamous-cell carcinomas; relapse vs no
relapse); Kruskal–Wallis test for nondichotomous variables (T,
G)]. All tests used are described in Armitage et al (2002). Results
were considered statistically significant if Po0.05.
RESULTS
Clinicopathological characteristics
The mean age of the 126 male patients and 10 female patients was
64.6 years (range, 45–80 years; median age, 66 years). The most
common histologic type of tumour was squamous-cell carcinoma
(61.8%; 84 cases), followed by adenocarcinoma (30%; 41 cases),
large-cell anaplastic carcinoma (6%; eight cases) and bronchio-
loalveolar carcinoma (2.2%; three cases). According to the degree
of differentiation, the primary tumours were histopathologically
graded as well differentiated (G1, 28.7%), moderately differentiated
(G2, 41.9%) and poorly differentiated (G3, 29.4%). With respect to
tumour size, 54 (39.7%) cancers were classified as T1 and 82
(60.3%) were classified as T2. A total of 52 (38.23%) patients
presented relapses during follow-up: 13 of them developed local
recurrence, whereas 39 developed distant metastases. At the end of
the follow-up, 48 patients (35.3%) were alive, while 88 (64.7%) had
died.
Association between clinicopathological characteristics
and survival
In the sample of 136 stage I patients, among the clinicopathological
characteristics, only tumour grade was significantly associated
with disease-free survival (P¼0.0059). Indeed, none of the other
parameters showed a statistically significant correlation with
outcome (Table 1).
Association of OPN expression with clinicopathological
characteristics and survival
Osteopontin expression was analysed as a dichotomous variable,
using the median value of 20% as the cutoff point, and
distinguishing two categories: one with a high OPN expression
(X20%) and one with a low or null OPN expression (o20%). In
total, 65 (47.8%) cases showed high OPN expression, whereas in 71
(52.2%) cases OPN expression was low. Regarding the staining
intensity, 40 tumours showed a weak immunoreactivity, 36 an
intermediate staining and 22 a strong staining (Table 1).
Osteopontin expression was significantly correlated with sex
(P¼0.006) and tumour grade (P¼0.00004), and was also
significantly correlated with relapse (P¼0.02). In fact, a sig-
nificantly lower OPN expression was observed in female patients
(10 out of 136), in poorly differentiated (G3) tumours, and in
patients who did not relapse. On the other hand, there were no
significant associations of OPN expression with age (P¼0.25) and
histology (P¼0.75) (Table 2).
Univariate analysis showed that OPN expression was signifi-
cantly correlated with overall (P¼0.034) and disease-free
(P¼0.011) survival (Table 1). In multivariate analysis, both Cox
models contain only OPN expression. A high value of OPN
expression is unfavourable both to survival (risk ratio 1.88:1)
(P¼0.037) (Table 3) and relapse (risk ratio 2.08:1) (P¼0.013)
(data not shown).
Figures 2 and 3 represent Kaplan–Meier curves for overall
survival (Figure 2) and disease-free survival (Figure 3), respec-
tively. Patients were divided according to high or low OPN
expression. One can see that patients were significantly split by
OPN expression regarding both overall (P¼0.034) and disease-
free (P¼0.011) survival; in fact, stage I NSCLC patients with high
Table 1 Univariate analysis of the associations between prognostic
variables and overall survival or disease-free survival in 136 cases of stage I
non-small-cell lung cancer
Patient and tumour
characteristics
Number of
cases
P-value overall
survival
P-value disease-
free survival
Sex
Male 126
Female 10 0.37 0.56
Age (years)
p66 64
466 72 0.48 0.47
Tumour grade (G)
G1 39
G2 57
G3 40 0.070 0.0059
Histology
Squamous 84
Nonsquamous 52 0.79 0.88
Tumour size (T)
T1 54
T2 82 0.39 0.37
Osteopontin expression (OPN %)
Low (o20) 65
High (X20) 71 0.034 0.011
Osteopontin (OPN+)
03 8
+4 0
++ 36
+++ 22 0.11 0.090
Table 2 P-values of Mann–Whitney t-test and Kruskal–Wallis tests
comparing OPN expression and different clinicopathological characteristics
in 136 cases of stage I non-small-cell lung cancers
OPN %
Sex 0.006
Age 0.25
Histology 0.75
G 0.00004
Relapse 0.02
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those with low OPN expression.
DISCUSSION
The observation that OPN is involved in tumorigenesis, progres-
sion and metastatic dissemination of different types of human
tumours, such as breast (Tuck et al, 1997; Tuck and Chambers,
2001), prostate (Thalmann et al, 1999), colon (Agrawal et al, 2002),
ovarian (Kim et al, 2002), gastric (Ue et al, 1998) and lung
(Chambers et al, 1996) cancer, has opened an interesting field of
research, both for its possible prognostic significance in terms of
disease-free and overall survival, and for its eventual role as a
specific target in designing new anticancer therapies. Recently, an
interesting study has shown an OPN immunostaining in many
other tumours, such as pancreatic, renal, endometrial, oesophageal
and head and neck carcinomas (Coppola et al, 2004).
As a consequence, in the present study, we decided to focus
our interest on OPN protein expression detected by IHC in a
large sample (136 cases) of NSCLCs, since these tumours still have
a poor prognosis, in spite of remarkable advances in diagnosis,
staging, treatment and biological characterisation. In order
to establish whether OPN could be a prognostic marker for
NSCLC, we analysed the correlations between OPN expression and
many clinicopathological parameters, such as age and sex
of patients, primary tumour size, histological type, local recurrence
and, particularly, disease-free and overall survival. We decided
to study in particular the subgroup of NSCLC with stage I (T1/2N0)
tumours, because we think it could be very important to
identify subsets of patients, who could possibly benefit
from adjuvant chemoradiotherapy and, eventually, from new
therapeutic trials, from among those with tumours resected in
early stage.
As far as we know, our study is the largest prospective analysis
of the prognostic role of OPN expression in patients with NSCLC
treated with curative surgery. In our sample, OPN expression was
analysed as a dichotomous variable, using the median value of 20%
as the cutoff point, and distinguishing two categories: one with a
high OPN expression (X20%) and one with a low OPN expression
(o20%). In contrast to recent studies (Shijubo et al, 1999; Zhang
et al, 2001; Coppola et al, 2004), we did not use a score, which
combines the percentage of immunoreactive tumour cells with
their staining intensity, because we considered this latter to be a
highly subjective parameter (we evaluated staining intensity only
as a descriptive parameter). According to the criteria we adopted,
we found that 65 (47.8%) NSCLC had a high OPN expression,
whereas in 71 (52.2%) cases OPN expression was low.
Osteopontin expression level was significantly correlated with
overall and disease-free survival, both in univariate and in
multivariate analyses; so, a high value of OPN expression is seen
to be unfavourable both to survival (risk ratio 1.88:1) and relapse
(risk ratio 2.08:1).
This result agreed with the conclusions of the study conducted
on 82 NSCLCs by Schneider et al (2004), who showed a statistically
significant association between high OPN expression and shorter
survival, and with the results of one of the first works on OPN
expression in 25 lung cancer patients carried out by Chambers et al
(1996), who observed a higher OPN immunoreactivity in tumour
specimens from patients who had died during follow-up.
As regards the association between OPN expression and
clinicopathological parameters, such as age, sex, histological type,
primary tumour size, histological grading, relapses during follow-
up and status (alive vs dead), we observed statistically significant
correlations between OPN expression and grading (P¼0.00004),
sex (P¼0.006) and relapse (P¼0.02).
The fact that patients with poorly differentiated (G3) tumours
showed a significantly lower OPN expression than those with well-
Table 3 Multivariate analysis of overall survival according to Cox’s model
for stage I patients (final model obtained with a backward stepwise
regression)
b exp(b) s.e. exp(b) zP -value
OPN % high 0.631 1.88 0.303 2.08 0.037
Likelihood ratio test¼4.53 on 1 df, P¼0.033, n¼136. Proportional hazard test
P¼0.09. b¼Cox regression’s coefficient, exp(b)¼risk ratio, z¼Wald statistics,
P¼Wald’s test P-value.
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Figure 2 Kaplan–Meier curves for overall survival. Curve 1: Tumour
stage I, low OPN expression, mean survival MS 107 months, standard error
(s.e.) 6 months. Curve 2: Stage I, high OPN, MS 84 months, s.e. 6 months.
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Figure 3 Kaplan–Meier curves for disease-free survival. Curve 1:
Tumour stage I, low OPN expression, mean survival MS 104 months,
standard error (s.e.) 7 months. Curve 2: Stage I, high OPN, MS 73 months,
s.e. 7 months.
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explained by considering that in highly undifferentiated tumours
the loss of cellular differentiation could be responsible for an
increasing reduction of OPN protein expression.
The observation that OPN was expressed at lower levels in stage
I female patients compared to male patients needs to be considered
with caution, because in our study there was an imbalance in
sample collection between men (126 cases) and women (10 cases);
this imbalance did not depend on the way we selected our case
history, because we chose to study a cohort of patients who had
consecutively undergone surgical resection.
Interestingly, we did not describe significant differences between
histological subgroups in terms of OPN expression (P¼0.75). Our
conclusion differs from those arrived at by Zhang et al (2001), who
observed a preferential OPN expression in squamous-cell carci-
nomas (OPN immunoreactivity in 68.8% of squamous-cell
carcinomas vs 20.8% of adenocarcinomas), and from those of
Shijubo et al (1999), who described a significantly worse prognosis
of stage I adenocarcinomas as compared to other groups, but
matches that of the Schneider group’s study (Schneider et al,
2004).
To sum up, in our study, a high OPN expression results as an
unfavourable prognostic factor for relapse and outcome in stage I
patients, and is a valid parameter by which to split this
subpopulation into two groups, both for overall and for disease-
free survival. This conclusion has notable importance in terms of
both the biological characterisation of early-stage tumours and
new therapeutic opportunities.
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